Advanced IBD Care in Wellington: A Patient’s Guide to Biologics and Biosimilars

Biologics and biosimilars have transformed the treatment of Crohn’s disease and ulcerative colitis — and they are changing what advanced IBD care costs.

Navigating life with Inflammatory Bowel Disease (IBD)—which includes Crohn’s disease and ulcerative colitis—means making many important healthcare decisions. In recent years, one of the most critical advances in gastrointestinal medicine has been the introduction of biologic therapies, and more recently, their highly similar counterparts: biosimilars.

At Gastro In Florida and the Wellington Digestive Institute, we are dedicated to providing our patients with the most effective, cutting-edge treatments. Under the leadership of board-certified gastroenterologist Dr. Vikram Tarugu, our practice prioritizes patient education, helping you make informed decisions about your IBD management journey.

This guide will explain what these medications are, list the commonest options available, and explore how they are transforming the affordability of advanced IBD care in South Florida.

What Are Biologics and Biosimilars?

To understand a biosimilar, you first need to understand the medication it is based on.

Biologics are complex medications created from living cells rather than chemicals. They are designed to be extremely targeted, disrupting specific proteins or pathways in the immune system that cause the chronic, destructive inflammation characteristic of IBD. For decades, they have been the gold standard for managing moderate-to-severe Crohn’s and colitis.

Here is a simple visualization comparing how these drug classes differ in complexity and origin:

A biosimilar medication (such as those listed below) is essentially a “highly similar” version of a reference biologic. It is developed once the original drug’s patent expires.

Importantly, biosimilars are NOT “generic versions” in the traditional chemical sense, because living systems cannot make exact copies. However, the FDA confirms that biosimilars have no clinically meaningful differences from the original biologic. They work the same way, require the same dosing, have the same safety profile, and provide the same therapeutic benefits.

The Commonest Biosimilars We Use in IBD Care

In current IBD practice, the vast majority of biosimilars are approved to treat Crohn’s disease and ulcerative colitis. They are approved based on successful clinical trials that demonstrate equivalence to the reference product.

If Dr. Tarugu recommends an anti-TNF therapy for you, he may discuss these common biosimilars:

Biosimilars of Infliximab (Reference Product: Remicade®)

• Inflectra® (infliximab-dyyb)
• Renflexis® (infliximab-abda)
• Avsola® (infliximab-axxq)

These are administered via an in-office infusion, typically every 8 weeks, following an initial loading dose period.

Biosimilars of Adalimumab (Reference Product: Humira®)

• Amjevita® (adalimumab-atto)
• Cyltezo® (adalimumab-adbm) – Notably, this was the first designated as interchangeable by the FDA.
• Hyrimoz® (adalimumab-adaz)
• Hadlima® (adalimumab-bwwd)
• (and several others, as the adalimumab market is rapidly expanding)

These are administered via a self-injection pen or syringe, usually every two weeks.

How Biosimilars Affect IBD Care Economics

The introduction of biosimilars into clinical practice is a game-changer, not just medically, but economically. They provide a vital mechanism to expand access to life-changing IBD therapies while lowering healthcare spending.

Here is how the economics shift when biosimilars enter the market:

1. Reduced Cost to Patients and Payers

Biosimilars are typically introduced at a significantly lower price point than the reference biologic. When a patent expires, multiple manufacturers can produce biosimilars, driving a competitive market. This competition helps reduce the list price of these essential medications by 15% to 30%, or more.

For patients, this can mean a substantial reduction in copayments and out-of-pocket expenses, depending on your insurance structure. This affordability is crucial for long-term adherence to therapy.

2. Enhanced Long-Term Sustainability

The cost of treating chronic conditions like IBD has been rising globally. Biosimilars help slow this expenditure. The realized savings to the U.S. healthcare system from biosimilar use between 2015 and 2024 is estimated at roughly $36 billion. Continued and expanded use of biosimilars is critical for ensuring that high-quality, advanced IBD care remains financially sustainable for insurers and healthcare providers.

This infographic summarizes the virtuous cycle that biosimilars create in healthcare economics:

3. Optimized Treatment and Access Dynamics

Lower costs enable healthcare providers to optimize how they deliver care. By incorporating biosimilars through efficient in-office utilization models (such as those at our Wellington facility), we can streamline the treatment process for patients who need infusions. Lower therapy costs also mean that some patients may be able to access highly effective biologic therapies earlier in their disease course, potentially preventing complications and improving outcomes.

Personalized Gastroenterology in Wellington and Okeechobee

Choosing a treatment plan for IBD is complex and must be highly personalized. While biosimilars offer exciting economic benefits and identical clinical efficacy, they are not appropriate for every scenario, and insurance coverage can vary greatly.

Dr. Vikram Tarugu and the expert team at Gastro In Florida are here to guide you through every therapeutic choice. We evaluate your unique disease activity, medical history, and personal preferences to determine the best treatment strategy—whether that involves standard biologics, innovative biosimilars, or other modalities.

Don’t let navigating advanced IBD therapy options feel overwhelming. Receive care from a trusted local specialist dedicated to your digestive health.

Gastro In Florida and the Wellington Digestive Institute proudly serve patients across Wellington, Okeechobee, and the greater South Florida region.

Contact our office today to schedule your consultation and take the next step toward IBD remission.

Call Gastro in Florida at (863) 824-3447 (Okeechobee) or (561) 767-8342 (Wellington), or book a televisit.

---